Mangoceuticals, Inc. is primarily focused on developing, marketing, and selling a variety of men’s health and wellness products and services via a secure telemedicine platform. The Company has developed and is commercially marketing a new brand of erectile dysfunction (ED) products under the brand name Mango and a brand of hair loss products under the brand name Grow. These products are produced at a compounding pharmacy using a proprietary combination of United States Food and Drug Administration (FDA) approved ingredients and are available to patients on the determination of a prescribing physician that the compounded drug is necessary for the individual patient. It is marketing and selling these branded ED and hair loss products exclusively online via its Website at www.MangoRx.com. Its customer platform connects consumers to licensed healthcare professionals through its Website for the provision of care via telehealth. It also owns a global patent portfolio of oral solution.
BörsenkürzelMGRX
Name des UnternehmensMangoceuticals Inc
IPO-datumMar 21, 2023
CEOMr. Jacob D. Cohen
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeMar 21
Addresse15110 Dallas Pkwy, Suite 600
StadtDALLAS
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl75248
Telefon18336264679
Websitehttps://www.mangorx.com/
BörsenkürzelMGRX
IPO-datumMar 21, 2023
CEOMr. Jacob D. Cohen
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten